T Cell News and Research

Latest T Cell News and Research

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair. The study is published in the Aug. 13 edition of the journal Molecular Cell.

13 Aug 2010

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

The American Society of Hematology has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released today in Blood, ASH's premier scientific journal, in the article titled "Enhancing Research in Regenerative Medicine."

13 Aug 2010

OriGene Technologies announces acquisition of Blue Heron Biotechnology

OriGene Technologies, Inc., a gene-centric life sciences company, announces the acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business since 1999.

13 Aug 2010

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal a new 510(k) clearance for its Amicus® blood cell separator.

13 Aug 2010

Research finds genetic roots of alcoholism in humans

A novel mutation found in a mouse gene might provide new insights into the genetic roots of alcoholism in humans, according to a study led by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco. The study is published August 12th in the open-access journal PLoS Genetics.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

NYBC calls for blood donations

New York Blood Center, serving more than 20 million people in New York City, Long Island, the Hudson Valley, New Jersey, and parts of Connecticut and Pennsylvania, calls upon the communities it serves to remember your neighbors during this slow, late summer period for blood donations – and schedule a donation appointment or consider sponsoring a blood drive, because patients' needs do not take a summer break.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

In-car coach has strongest effect on drivers prone to distraction: Research

Although many states have banned using handheld cell phones at the wheel, a ban is difficult to enforce, and doesn't cover the growing number of gadgets now available.

12 Aug 2010

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

12 Aug 2010

Research reveals link between perception of intentions and evaluation of behavior

People generally like to see generous people rewarded and selfish people punished. Now, new research reveals a critical link between how we perceive another's intentions and our evaluation of their behavior. The study, published by Cell Press in the August 12 issue of the journal Neuron, makes some intriguing observations about how a description of the impact of an individual's actions on a group can alter the neural representation of their observed behavior.

12 Aug 2010

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

Getting a good night's sleep often comes down to technique. Avoiding late-night technology use and keeping a regular sleep schedule are two important techniques to heed as kids head back to school.Recent studies found that adolescents used multiple forms of technology late into the night, including gaming systems, cell phones, and computers. As a result, they demonstrated difficulty staying awake and alert throughout the day.

12 Aug 2010

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Seattle Genetics, Inc. announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.

12 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

T Cell News and Research

Latest T Cell News and Research

Study finds Olaparib can reduce tumor size in ovarian cancer women

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

Merlin protein controls adult cell activity to cause liver cancer

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

OriGene Technologies announces acquisition of Blue Heron Biotechnology

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Research finds genetic roots of alcoholism in humans

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

NYBC calls for blood donations

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

In-car coach has strongest effect on drivers prone to distraction: Research

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Research reveals link between perception of intentions and evaluation of behavior

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in